Platform Expansion (Inferred R&D)

About Instanosis

Instanosis is an early-stage, private diagnostics company focused on revolutionizing point-of-care testing through its proprietary InstaStrip technology, which offers dramatically higher sensitivity than traditional lateral flow assays. The company's initial commercial focus is on the opioid crisis, with FDA-cleared, CLIA-waived rapid tests for fentanyl, xylazine, and nitazene in urine and powders, targeting hospitals, harm reduction programs, and law enforcement. Backed by NIH funding and peer-reviewed clinical validation, Instanosis is positioned to address critical gaps in rapid, accurate drug screening and has a pipeline leveraging its platform for other diagnostic applications.

Therapeutic Areas